Anti-CXCR4-dasatinib ADC

  • 1.00 Dollar US$
  • Published date: November 29, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CXCR4 monoclonal antibody conjugated via a linker to dasatinib. Dasatinib, also known as BMS-354825, is a cancer drug. It is an oral Bcr-Abl tyrosine kinase inhibitorand Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Result 0 votes
Bella
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-DLL3 (clone SC16.15)-PBD dimers ADC

    Anti-DLL3 (clone SC16.15)-PBD dimers ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-DLL3 monoclonal antibody (clone SC16.15) conjugated via a linker to PBD dimers. The PBD dimers is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocyto...

  • Anti-CXCR4-PEG-S-4FB-dasatinib ADC

    Anti-CXCR4-PEG-S-4FB-dasatinib ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CXCR4 monoclonal antibody conjugated via a PEG-S-4FB linker to dasatinib. Dasatinib, also known as BMS-354825, is a cancer drug. It is an oral Bcr-Abl tyrosine kinase inhibitorand Src family tyrosine kinase in...

  • Anti-CXCR4 (ulocuplumab)-pAcF-MMAF ADC

    Anti-CXCR4 (ulocuplumab)-pAcF-MMAF ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CXCR4 monoclonal antibody (ulocuplumab) conjugated via a pAcF linker to a MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. W...